Sixteen males and two females with symmetrical (mild) type of chondrodysplasia punctata were tested for mutations in the X chromosome located arylsulphatase D and E genes. We identified one nonsense and two missense mutations in the arylsulphatase E gene in three males. No ARS-E, and ARS-F).9 Missense mutations in the ARS-E gene were present in five patients with CDPX, strongly suggesting that CDPX is caused by arylsulphatase E deficiency. No families were studied however. We have tested 16 males and two females who have symmetrical CDP for the presence of mutations in the coding regions of the ARS-D and ARS-E genes. We report the clinical findings, identification, and segregation of three novel mutations in the ARS-E gene in three families with symmetrical CDP.
Chondrodysplasia punctata (CDP) refers to a group of bone dysplasias characterised by punctate changes in infants seen radiologically around developing epiphyses. A number of distinct types can be recognised and the cause can be primary, usually genetic, or secondary owing to side effects of drug ingestion during pregnancy or a consequence of certain storage diseases.' 2 We have classified 93 ARS-E, and ARS-F).9 Missense mutations in the ARS-E gene were present in five patients with CDPX, strongly suggesting that CDPX is caused by arylsulphatase E deficiency. No families were studied however. We have tested 16 males and two females who have symmetrical CDP for the presence of mutations in the coding regions of the ARS-D and ARS-E genes. We report the clinical findings, identification, and segregation of three novel mutations in the ARS-E gene in three families with symmetrical CDP.
Materials and methods

PATIENTS
The 16 males and two females with symmetrical SCDP analysed in this study all had the diagnosis made by showing puncta radiologically. They had been part of a previous study of the classification of SCDP by Sheffield et a3 ' and six of these males had been analysed, but no mutations found, by SSCP for ARS-D and ARS-E mutations in the initial study that defined ARS-E as the causative mutation in CDP.9 Brachytelephalangic CDP was not classified separately from SCDP because we had previously concluded that they were the same entity. showed that the exon 4 and 6 mutations were missense mutations and the exon 10 mutation introduced a premature stop codon. The families of these patients were studied to document segregation of the mutation, with two of the three families having a previously known family history (fig 1) . The mutations were found in three of the 10 male patients not studied previously and represent a 30% detection rate of mutations.
FAMILY A
The male proband ( fig 1) was first seen at 2 years of age because of maternal concern about his facial appearance. He had a depressed nasal tip, noted from birth, and had short fingers. On examination, maxillary hypoplasia was noted with a flattened nasal tip and short columella characteristic of chondrodysplasia punctata. He was on the 50th height centile and had short terminal phalanges of the hand (brachytelephalangy). Clinically he was thought to be typical of brachytelephalangic chondrodysplasia punctata. Skeletal survey showed small, indefinite punctate calcifications on the medial side of the right ankle and hypoplasia and dysplasia of the calcaneal and talar bones. Minor dysplastic changes were present at the medial distal femoral ossification centres. The distal phalanges in both hands were short and dysplastic. His mother was asymptomatic and was of normal height with normal facies. The family history showed that a male sib had been stillborn with a diagnosis of chondrodysplasia punctata and anoxia. A skeletal survey in this sib showed punctate calcification around the femoral head and along the vertebrae. Histology of the femoral head showed abnormal matrix morphology and staining with clustering of the chondrocytes into islands surrounded by matrix with patchy reduction in proteoglycan (alcian blue positive and safronin 0 positive staining). In the femoral head there was one large lesion surrounded by numerous smaller lesions. The vertebral body examined Following SSCP analysis we identified a G to C change in ARS-E exon 4 (at nucleotide 477) of the male proband. This results in a glycine to alanine substitution at amino acid 137 (G137A) (fig 2) . The asymptomatic maternal grandfather also carries this mutation and the clinically normal mother is heterozygous for the mutation. DNA sequence analysis failed to detect the base change in 18 chromosomes from other CDP patients and 22 chromosomes from unaffected controls. 13 The G3 17R mutation (family A) has not previously been reported. It is present in a part of the ARS-E protein that is highly homologous to related sulphatases (fig 2) . A glycine residue is also found in this position in ARS-A, -C, and -D. The glycine to arginine substitution is likely to have consequences for protein structure by changing a polar amino acid to a basic amino acid. The proband in the family had the classical mild type of SCDP (normal height, brachytelephalangy, and normal intelligence with flattened nose as the only clinical manifestation).
The G137A mutation (family B) is also novel, but a glycine to valine mutation at the same amino acid (G1 37V) has been described. 9 The glycine is present in related human sulphatases and located in a highly conserved region in these enzymes (fig 2) . The mutation site has been described as crucial for the secondary structure of the arylsulphatases as judged by a severe impairment of processing and stability of arylsulphatase B in a patient with Maroteux-Lamy syndrome. In this patient, a G137V mutation was observed in the arylsulphatase B gene.'4 It is thus surprising that the phenotype in this family is so mild with a proband on the 90th centile for height without brachytelephalangy and a transmitting grandfather who is asymptomatic.
The codon 581 A to G mutation in exon 10 (family C) introduces a translation stop codon, resulting in premature termination of the protein by nine amino acids. This is the first example of a nonsense mutation in the ARS-E gene causing CDP. Clinically the proband is the most severely affected of the three patients described here (very flat nose, short stature, other dysmorphic signs, and sensorineural deafness). This suggests an important role of the C-terminal end of the protein chain in enzyme stability or function. This family is also the first family described in which there is segregation of an ARS-E mutation which correlates with affected phenotype. However, the affected uncle with the same mutation was not as severely affected.
The genetics of CDP is complicated. The ARS-D, ARS-E, and ARS-F genes are located approximately 150 kb from the pseudoautosomal boundary in the X specific region, but they escape normal X chromosome inactivation. 9 In all of our three families there were females of normal stature with normal facies who were shown to transmit the mutation, suggesting recessive inheritance. The sex ratio of cases seen is 2:1 (male to female),3 although we only studied two affected female patients in the current study. There is an X linked dominant form of CDP but this is clearly separated from SCDP on clinical grounds and is thought to have a separate locus at Xq28. '5 The mode of inheritance of SCDP is also not clearly known. Maroteux proposed that brachytelephalangic CDP was X linked.6 8 The probands in family A and C did have brachytelephalangy, whereas family B did not. We found in a previous clinical study that the presence of brachytelephalangy merely related to whether puncta were present in the terminal phalanges and one could not differentiate patients with or without brachytelephalangy on other clinical features. Furthermore, there were subjects who had short terminal phalanges on some digits and not on others. The fact that family B did not have brachytelephalangy shows that this is not necessarily a feature of CDPX or of mutations in the ARS-E gene and supports the above conclusion that symmetrical CDP encompasses the subgroup of brachytelephalangy.
We have previously suggested that SCDP is a useful description of cases of CDP that appear clinically indistinguishable.3 These cases have been labelled as mild,5 brachytelephalangic,6 and X linked recessive with chromosomal deletion. In lumping all our cases together as SCDP4 on clinical and radiological grounds we may be combining cases resulting from more than one gene locus. However, our finding of three mutations in the 10 male patients who were not analysed for mutations in the study of Franco et al9 suggests that at least 30% of cases of SCDP are X linked and that mutations in the ARS-E gene are a major cause of SCDP. This in turn establishes X linkage as an important mode of inheritance. Most cases of SCDP do not have a known family history, so finding an ARS-E mutation enables genetic counselling regarding the inheritance mode.
We have identified mutations in ARS-E in 30% of our patients. In the previous study, mutations were found in approximately 20% of patients.9 The two studies found that 50% of identified mutations in the ARS-E gene were in exon 4. Furthermore, all mutations found in the two studies were different. SSCP analysis would be expected to detect a much higher proportion of mutations if they are present and this raises the possibility that some of the patients have SCDP not resulting from ARS-E mutations. We have tested 16 male and two female patients for nucleotide changes in the ARS-D gene, but no mutations were found. The ARS-F gene was not analysed. It is therefore possible that mutations in other genes are responsible for a subset of SCDP cases.
It is also important to note the grandfather in family B, who had a normal facies and stature and transmitted the mutation. It is not clear why the gene defect manifested itself only in the grandson. However, it may be because the nose grows out with age and adults with the condition can be much less confidently diagnosed. In fact, our previous clinical study predicted that there would be some asymptomatic "affected" parents as so few patients had a clear cut X linked family history. This missense mutation is associated with the mildest phenotype and this is shown in the proband (typical facies and initial growth retardation resulting in an adult ofnormal height). In contrast, the stop mutation in family C is associated with a more severe phenotype.
We have shown segregation of ARS-E mutations for the first time and shown that asymptomatic females and males can transmit the mutations. We identified ARS-E mutations in 30% of males with SCDP, suggesting that some patients with SCDP have mutations in other genes. We have also tested the ARS-D gene, but as in the earlier study9 no mutations were detected. However, the finding of three families where ARS-E mutations segregate with SCDP allows further definition of the phenotype, prognosis, and molecular pathology of SCDP.
